Ambry Genetics Announces the Addition of Array CGH Services through Partnership with Baylor College of Medicine

FOR IMMEDIATE RELEASE

Ambry Genetics
15 Argonaut
Aliso Viejo, CA 92656

Aliso Viejo, CA, May 5, 2009 - Ambry Genetics announces the implementation of Comparative Genomic Hybridization (CGH) using oligonucleotide arrays through a partnership with Baylor College of Medicine. Large chromosomal abnormalities that are associated with over 270 genetic syndromes can be easily identified via analysis of each 105K whole genome and mitochondrial array. The partnership with Baylor College of Medicine equips Ambry with an extensive library as a reference, as well as expert support for cytogenetics.

Ambry’s CSO, Anja Kammesheidt states, "The oligonucleotide array was developed at Baylor College of Medicine and has proven to be an essential diagnostic tool. We are extremely pleased to be able to offer these same services now directly through our laboratory. Array CGH is becoming an integral part in any comprehensive genetic assessment."

The recent advancements in DNA MicroArrays are revolutionizing diagnostics by providing the ability to perform targeted and genome-wide studies (GWAS). Array CGH is used to detect genome-wide chromosomal imbalances with a single laboratory test consisting of multiple probes targeting virtually all disorders detected by traditional cytogenetics and fluorescent in situ hybridization (FISH). Array CGH is designed for patients with unexplained developmental delay, autism spectrum disorders, dysmorphic features, unexplained mental retardation, and/or multiple congenital anomalies. Each array contains 105K oligonucleotide probes, spaced at 30K through the genome with increased density at disease loci. Abnormalities are confirmed with other methods such as traditional FISH or MLPA. The test offers high resolution, sensitivity, enhanced clinical detection rates, and greater accuracy in interpretation because of high coverage of clinically significant areas.


About This Report

This report contains forward-looking statements about the Company’s future plans, strategies, objectives, goals and expectations, including projections, estimates, prospects, returns and performance of the Company. Forward-looking statements can be identified by the use of forward-looking terminology such as "may," "will," "should," "expect," "anticipate," "estimate," "intend," "continue," or "believe" or the negatives thereof or other variations thereof or comparable terminology. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. In light of the significant uncertainties inherent in the forward-looking statements made in this report the inclusion of such information should not be regarded as a representation or warranty, express or implied, by the Company or any other person that the objectives and plans of the Company will be achieved.

About Ambry Genetics ®

Ambry Genetics is both College of American Pathologists (CAP)-accredited and Clinical Laboratory Improvement Amendments (CLIA)-certified. Ambry leads in clinical genetic diagnostics and genetics software solutions, combining both to offer the most comprehensive testing menu in the industry. Ambry has established a reputation for sharing data while safeguarding patient privacy, unparalleled service, and responsibly applying new technologies to the clinical molecular diagnostics market. For more information about Ambry Genetics, visit ambrygen.com.

Press Contact:
Aaron Schmidt
Sr Manager, Communications
aschmidt@ambrygen.com
949 457 4679

Search Results

Start your search...